Title:
An international survey on the impact of COVID-19 in individuals with Down syndrome
Authors:
Anke Hüls, Alberto C. S. Costa, Mara Dierssen, R. Asaad Baksh, Stefania Bargagna, Nicole T. Baumer, Ana Claudia Brandão, Angelo Carfi, Maria Carmona-Iragui, Brain Allen Chicoine, Sujay Ghosh, Monica Lakhanpaul, Coral Manso, Miguel-Angel Mayer, Maria del Carmen Ortega, Diego Real de Asua, Anne-Sophie Rebillat, Lauren Ashley Russell, Giuseppina Sgandurra, Diletta Valentini, Stephanie L Sherman & Andre Strydom
Published:
medRxiv, 5 November 2020
[Keep in mind that this article is a preprint and not yet peer reviewed.]
Abstract:
Background:
Health conditions and immune dysfunction associated with trisomy 21 (Down syndrome, DS) may impact the clinical course of COVID-19 once infected by SARS-CoV-2.
Methods:
The T21RS COVID-19 Initiative launched an international survey for clinicians or caregivers/family members on patients with COVID-19 and DS (N=1046). De-identified survey data collected between April and October 2020 were analysed and compared with the UK ISARIC4C survey of hospitalized COVID-19 patients with and without DS. COVID-19 patients with DS from the ISARIC4C survey (ISARIC4C DS cases=100) were matched to a random set of patients without DS (ISARIC4C controls=400) and hospitalized DS cases in the T21RS survey (T21RS DS cases=100) based on age, gender, and ethnicity.
Finding:
The mean age in the T21RS survey was 29 years (SD=18), 73% lived with their family. Similar to the general population, the most frequent signs and symptoms of COVID-19 were fever, cough, and shortness of breath. Pain and nausea were reported less frequently (p<0.01), whereas altered consciousness/confusion were reported more frequently (p<0.01). Risk factors for hospitalization and mortality were similar to the general population (age, male gender, diabetes, obesity, dementia) with the addition of congenital heart defects as a risk factor for hospitalization. Mortality rates showed a rapid increase from age 40 and were higher than for controls (T21RS DS versus controls: risk ratio (RR)=3.5 (95%-CI=2.6;4.4), ISARIC4C DS versus controls: RR=2.9 (95%-CI=2.1;3.8)) even after adjusting for known risk factors for COVID-19 mortality.
Interpretation:
Leading signs/symptoms of COVID-19 and risk factors for severe disease course are similar to the general population. However, individuals with DS present significantly higher rates of mortality, especially from age 40.